Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
14 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:RARE) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table
Express News | Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $115 Price Target
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $70
Evercore analyst Liisa Bayko maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and adjusts the target price from $80 to $70.According to TipRanks data, the analyst has a success rate
Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $45 to $135
On Jul 19, major Wall Street analysts update their ratings for $Ultragenyx Pharmaceutical(RARE.US)$, with price targets ranging from $45 to $135.Evercore analyst Liisa Bayko maintains with a buy
Ultragenyx Pharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/18/2024 2.17% Wedbush $45 → $45 Reiterates Neutral → Neutral 06/12/2024 161.1% Cantor Fitzgerald $115 →
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Year to date, shares of Ultragenyx have lost 8.2% compared with the industry’s 1% decline.
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $72 to $135
On Jul 18, major Wall Street analysts update their ratings for $Ultragenyx Pharmaceutical(RARE.US)$, with price targets ranging from $72 to $135.Wells Fargo analyst Tiago Fauth maintains with a buy
Ultragenyx Pharmaceutical (RARE) Receives a Hold From Wedbush
Ultragenyx Pharmaceutical: A Strong Buy on GTX-102's Promising Trajectory in Angelman Syndrome Treatment
Piper Sandler Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Express News | Ultragenyx Pharmaceutical: Phase 3 Study on Track to Initiate by End of This Year
Express News | Ultragenyx Aligns With FDA On Phase 3 Study Endpoints For GTX-102; Phase 3 Study To Initiate By Year-End; Successful End-Of-Phase 2 Meeting Supports Plans For Global Double-Blind Sham-Controlled Pivotal Study; Additional Study Planned For Patients...
Express News | Ultragenyx Announces Successful End-of-Phase 2 Meeting With FDA for Gtx-102 Angelman Syndrome Program
Ultragenyx Pharmaceutical Buy Rating Justified by Strong GTX102 Prospects and Positive Regulatory Outlook
Renowned Rare-Disease Drug Developer Emil Kakkis, M.D., Ph.D., to Join Actio Biosciences Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared
There Is A Reason Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Price Is Undemanding
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) price-to-sales (or "P/S") ratio of 9.3x might make it look like a buy right now compared to the Biotechs industry in the United States, where around
Morgan Stanley Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $65
Morgan Stanley analyst Jeffrey Hung maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate
Morgan Stanley Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)